Datasheet is currently unavailable. Try again or CONTACT US
Datasheet

Sars Nucleocapsid Protein Antibody

Rabbit Polyclonal

200-401-A50
500 µg
ELISA; WB; FC; IF
Virus
Rabbit
Have a Question? Ask a Specialist
$456.00 /Per Item
Availability: Ships next business day
Shipping info:

$50.00 to US & Canada for most products. Final costs are calculated at checkout.

Description

Background

The coronavirus nucleocapsid protein is the major structural component of virions that associates with genomic RNA to form a long, flexible, helical nucleocapsid.  Sequence comparison of the N genes of five strains of the coronavirus mouse hepatitis virus suggests a three-domain structure for the nucleocapsid protein. Anti-SARS-CoV Nucleocapsid (N) Protein Antibody is useful for researchers interested in viral research.

Synonyms

rabbit anti-Sars Nucleocapsid Protein Antibody, rabbit anti-Sars-CoV Nucleocapsid (N) Protein Antibody, N antibody, N structural protein antibody, NC antibody, Nucleocapsid protein antibody, Nucleoprotein antibody, SARS coronavirus N protein antibody, SARS CoV antibody, SARSCoV antibody, Severe acute respiratory syndrome antibody, A50 Antibody, A50 SARS, COVID

Immunogen

This protein A purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a purified recombinant protein corresponding to full length SARS Coronavirus Nucleocapsid protein. Lifesensors Inc. (www.lifesensors.com) prepared the Nucleocapsid protein as follows: SUMO-Nucleocapsid fusion was expressed in E.coli in LB medium and purified using Ni-NTA resin (Qiagen) affinity chromatography. After the fusion was cleaved by the SUMO Protease (LifeSensors), the SUMO tag and protease were subtracted from the nucleocapsid using MAC and the nucleocapsid was finally purified using Cation Exchange Chromatography with the Macro-Prep High S resin (BioRad) and size exclusion chromatography.

Application Note

This protein A purified antibody has been tested for use in ELISA, western blot, Immunohistochemistry, Immunofluorescence, and lateral flow.  Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 46 kDa in size corresponding to SARS Nucleocapsid (N) protein by western blotting in the appropriate cell lysate or extract. ELISA and lateral flow format has been used to detect virus in extracts from nasal and throat swabs and saliva. IF has been used to determine the presence or absence of virus entering cells especially when anti-viral drugs are applied. IHC studies have been performed on biopsies, included retrospective studies on cadaver tissues after formalin fixation and paraffin embedding, detecting the coronavirus in lung, liver, bile duct, and placenta tissue. Yet other studies have shown this antibody has the ability to neutralize the virus and thereby protect cells from the uptake of live virus. Others have demonstrated the utility of the antibody in flow cytometry studies.

Purity/Specificity

This protein A purified antibody is directed against SARS Coronavirus Nucleocapsid (N) protein. The product was purified from monospecific antiserum by protein A affinity purification.  BLAST analysis was used to suggest reactivity with related Coronavirus proteins.  Cross reactivity with homologues from other sources has not been determined.

Storage Condition

Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Disclaimer Note-General

THE MATERIALS PROVIDED WITH THIS CERTIFICATE OF ANALYSIS (MATERIALS) ARE FOR RESEARCH USE ONLY AND SUBJECT TO A LIMITED USE LICENSE. BY USING THIS PRODUCT, THE USER AGREES TO BE BOUND BY THE TERMS OF THE LIMITED USE LICENSE. If the user is not willing to accept the terms of this limited use license and the product is unused, Rockland will accept return of the unused product and provide the user with a full refund. Pursuant to the limited use license, the user may use the product for research use only. NO TRANSFER OR COMMERCIAL USE OF THIS PRODUCT IS ALLOWED. Commercial use means a use of the product in exchange for consideration, including use in the manufacture of a product, use of the product in the provision of services, and the resale of the product. Rockland reserves all other rights not permitted under the license granted herein, including the rights which are embodied in other products or materials derived from the use of the Materials or know-how embodied in the Materials. NO RIGHT IS GRANTED UNDER THE LICENSE TO MODIFY OR OTHERWISE CREATE DERIVATIVES OR VARIATIONS OF THE PRODUCT OR TO USE ROCKLAND’S KNOW-HOW OR OTHER INTELLECTUAL PROPERTY FOR OTHER USES. No other use of this product is authorized without the express written prior consent of Rockland, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, therapeutic uses, or any type of consumption by or application to humans or animals. For uses outside the limited use license, including any diagnostic, therapeutic or commercial use, please contact Rockland for supply and licensing information at licensing@rockland-inc.com. Products are warranted to operate or perform substantially in conformance with product specifications in effect at the time of shipment, as set forth in the product documentation, specifications and/or package inserts (“Documentation”). The warranty provided is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from the date of shipment when the product is subjected to normal, proper, and intended usage and storage. This warranty does not extend to anyone other than the buyer. No claim of suitability for use in applications regulated by the FDA is made. Any sample furnished to the buyer is merely illustrative of the general type and quality of goods and does not represent that any product will conform to such sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED, INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY. BUYER’S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT, OR REFUND FOR THE NON-CONFORMING PRODUCTS AT SELLER’S SOLE OPTION. There is no obligation to repair, replace, or refund for products as the result of (1) accident, disaster, or event of force majeure, (2) misuse, fault, or negligence of or by the buyer, (3) use of the products in a manner for which they are not designed, or (4) improper storage or handling of the products. In no event shall Rockland be responsible or liable in any way for any third party intellectual property that may address, or is necessary for, use of this product other than as expressly set forth above. The terms of this limited use license and warranties shall be governed by the laws of the Commonwealth of Pennsylvania.

Anti-SARS-CoV Nucleocapsid (N) Protein (RABBIT) Antibody - 200-401-A50
ELISA; WB
FC; IF
SARS
Virus
Rabbit
Unconjugated
Polyclonal
IgG
Recombinant Protein
Lyophilized
Ambient
Expiration date is one (1) year from date of opening.
5.3 mg/mL by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Restore with deionized water (or equivalent)
100 µL

Invalid lot number

If you need help finding your CofA, contact us

  • Human airway lineages derived from pluripotent stem cells reveal the epithelial responses to SARS-CoV-2 infection.;2022;Wang R et al.;PubMed
  • A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL pro inhibitor PF-00835231 as a potential new treatment for COVID-19.;2021;de Vries M et al.;PubMed
  • Histomorphological patterns of regional lymph nodes in COVID-19 lungs.;2021;Haslbauer JD. et al.;PubMed
  • A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry.;2021;Zhu Y. et al.;PubMed
  • A novel glucocorticoid and androgen receptor modulator reduces viral entry and innate immune inflammatory responses in the Syrian Hamster model of SARS-CoV-2.;2021;Rocha SM. et al.;PubMed
  • Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individual.;2021;Williamson MK et al.;PubMed
  • Young infants exhibit robust functional antibody responses and restrained IFN-γ production to SARS-CoV-2.;2021;Goenka A et al.;PubMed
  • Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.;2021;Weingarten-Gabby S et al.;PubMed
  • Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.;2021;Lopez E et al.;PubMed
  • SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation.;2021;Sanders DW et al.;PubMed
  • Human airway lineages derived from pluripotent stem cells reveal the epithelial responses to SARS-CoV-2 infection.;2021;Wang R et al.;PubMed
  • DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist.;2021;Thepaut M et al.;PubMed
  • Evaluation of the Roche antigen rapid test and a cell culture-based assay compared to rRT- PCR for the detection of SARS-CoV-2: A contribution to the discussion about SARS-CoV-2 diagnostic tests and contagiousness.;2021;Steinlin-Schopfer J et al.;PubMed
  • Structure and mechanism of SARS-CoV-2 Spike N679-V687 deletion variant elucidate cell-type specific evolution of viral fitness.;2021;Gupta K et al.;PubMed
  • Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: a source of immune escape variants.;2021;Weigang S et al.;PubMed
  • Interferon-alpha or-beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2.;2021;Klouda T et al.;PubMed
  • The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease.;2021;Avolio E et al.;PubMed
  • Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs.;2021;Pfafenrot C. et al.;PubMed
  • Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.;2021;Wheatley AK. et al.;PubMed
  • Acute SARS-CoV-2 infection in pregnancy is associated with placental ACE-2 shedding.;2021;Taglauer ES. et al.;PubMed
  • Protective Role of Combined Polyphenols and Micronutrients against Influenza A Virus and SARS-CoV-2 Infection In Vitro.;2021;De Angelis M et al.;PubMed
  • Rapid inactivation of SARS-CoV-2 with LED irradiation of visible spectrum wavelengths.;2021;De Santis R et al.;PubMed
  • Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: a source of immune escape variants.;2021;Weigang S et al.;PubMed
  • Lateral flow assays (LFA) as an alternative medical diagnosis method for detection of virus species: The intertwine of nanotechnology with sensing strategies.;2021;Sadeghi P et al.;PubMed
  • Pleural Mesothelial Cells Modulate the Inflammatory/Profibrotic Response During SARS-CoV-2 Infection.;2021;Matusali G et al.;PubMed
  • Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection.;2021;Koutsakos M et al.;PubMed
  • Tracking the kinetics and phenotype of spike epitope-specific CD4 T cell immunity in the context of SARS-CoV-2 infection and vaccination.;2021;Juno J et al.;PubMed
  • SARS-CoV-2 infection of olfactory epithelial cells and neurons drives acute lung injury and lethal COVID-19 in mice;2021;Tang AT et al.;PubMed
  • ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection.;2021;Ching KL et al.;PubMed
  • Engineered chimeric T cell receptor fusion construct (TRuC)-expressing T cells prevent translational shutdown in SARS-CoV-2-infected cells.;2021;Godbole I et al.;PubMed
  • Arrayed multicycle drug screens identify broadly acting chemical inhibitors for repurposing against SARS CoV 2.;2021;Murer LP et al.;PubMed
  • Characterisation of cardiac pathology in 23 autopsies of lethal COVID‐19.;2021;Haslbauer JD. et al.;PubMed
  • Histopathological features in fatal COVID-19 acute respiratory distress syndrome.;2021;Merdji H et al.;PubMed
  • Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.;2021;Ciccosanti F et al.;PubMed
  • Copper-Coated Polypropylene Filter Face Mask with SARS-CoV-2 Antiviral Ability.;2021;Jung S et al.;PubMed
  • SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway.;2021;Chen DY et al.;PubMed
  • Susceptibility of well-differentiated airway epithelial cell cultures from domestic and wildlife animals to SARS-CoV-2.;2021;Gultom M. et al.;PubMed
  • Multi-level inhibition of coronavirus replication by chemical ER stress.;2021;Shaban MS. et al.;PubMed
  • Antibody Screening Results for Anti-Nucleocapsid Antibodies Towards the Development of a SARS-CoV-2 Nucleocapsid Protein Antigen Detecting Lateral Flow Assay;2020;Cate D et al.;PubMed
  • Recapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids.;2020;Zhao B. et al.;PubMed
  • Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform.;2020;Thao T. et al.;PubMed
  • Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2.;2020;Holwerda M. et al.;PubMed
  • Identification of Drugs Blocking SARS-CoV-2 Infection using Human Pluripotent Stem Cell-derived Colonic Organoids.;2020;Duan X. et al.;PubMed
  • The Global Phosphorylation Landscape of SARS-CoV-2 Infection.;2020;Bouhaddou M, Memon D, Meyer B, et al.;PubMed
  • The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication.;2020;Loffredo M. et al.;PubMed
  • Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.;2020;Yurkovetskiy L. et al.;PubMed
  • SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response.;2020;Huang J, Hume AJ, Abo KM, et al.;PubMed
  • Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2.;2020;Liu Y. et al.;PubMed
  • Disparate temperature-dependent virus – host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium.;2020;V’kovski P. et al.;PubMed
  • Two distinct immunopathological profiles in autopsy lungs of COVID-19.;2020;Nienhold R. et al.;PubMed
  • A SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Towards the Development of Point of Care Tests Using Commercially Available Reagents.;2020;Grant BD, Anderson CE, Williford JR, et al.;PubMed
  • Neuropilin-1 is a host factor for SARS-CoV-2 infection.;2020;Daly JL.;PubMed
  • Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry.;2020;Ren W.;PubMed
  • A novel cell culture system modeling the SARS-CoV-2 life cycle.;2020;Xiaohui Ju et al;PubMed
  • Human Pluripotent Stem Cell Derived Intestinal Organoids Model SARS-CoV-2 Infection Revealing a Common Epithelial Inflammatory Response.;2020;Mithal A. et al.;PubMed
  • On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.;2020;Sauvat A et al.;PubMed
  • Cutaneous manifestations in patients with COVID-19: clinical and histological findings.;2020;Fattori A. et al.;PubMed
  • Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.;2020;Cervia C.et al.;PubMed
  • Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2.;2020;Hekman R. et al.;PubMed